<code id='60BB251A7D'></code><style id='60BB251A7D'></style>
    • <acronym id='60BB251A7D'></acronym>
      <center id='60BB251A7D'><center id='60BB251A7D'><tfoot id='60BB251A7D'></tfoot></center><abbr id='60BB251A7D'><dir id='60BB251A7D'><tfoot id='60BB251A7D'></tfoot><noframes id='60BB251A7D'>

    • <optgroup id='60BB251A7D'><strike id='60BB251A7D'><sup id='60BB251A7D'></sup></strike><code id='60BB251A7D'></code></optgroup>
        1. <b id='60BB251A7D'><label id='60BB251A7D'><select id='60BB251A7D'><dt id='60BB251A7D'><span id='60BB251A7D'></span></dt></select></label></b><u id='60BB251A7D'></u>
          <i id='60BB251A7D'><strike id='60BB251A7D'><tt id='60BB251A7D'><pre id='60BB251A7D'></pre></tt></strike></i>

          knowledge

          knowledge

          author:entertainment    Page View:89
          Good CEOs 2022
          Hyacinth Empinado/STAT

          It’s that time of the year again when I recognize the Best Biopharma CEO of the year.

          This year’s selection is so deservingly obvious that I won’t fabricate suspense by starting with an honor roll of runners-up. More on those high-achieving folks later. Let’s get right to the main course: David Ricks of Eli Lillyis the runaway, rock star, who-else-could-it-be Best Biopharma CEO of 2023.

          advertisement

          What an incredible year it’s been for Ricks and the Lilly executive team who helped him achieve so much. My colleague Matt Herper wrote earlier this year about the “dynamic duo” of Ricks and Chief Scientific Officer Dan Skovronsky.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati
          In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

          CourtesyBristolMyersSquibbBristolMyersSquibbsaidthatitwouldpurchaseMiratiTherapeutics,makerofthecanc

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          The future of health care in the House

          AlexHogan/STATYou’rereadingthewebeditionofD.C.Diagnosis. Signuphere toreceivethisnewsletterinyourinb